XORTX terminates IR agreement, delists TSXV
Analysis based on 7 articles · First reported Aug 28, 2026 · Last updated Aug 28, 2026
The termination of the IR agreement and return of funds may reduce near-term marketing expenses but also signals reduced investor outreach, potentially dampening investor sentiment. The voluntary delisting from the TSX Venture Exchange could reduce liquidity and visibility for Canadian investors, while the company remains listed on Nasdaq.
XORTX Therapeutics Inc. announced on August 28, 2026 that it terminated its investor relations and marketing agreement with IR Agency LLC, effective August 7, 2026. The agreement, dated May 13, 2026, had a 90-day term and a fee of US$2.5 million, which was fully paid in advance. Under mutual agreement, the arrangement was rescinded, services discontinued, and the funds returned to XORTX on August 14, 2026. The company postponed its investor relations program while it completes its voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. XORTX also announced that Computershare will become its transfer agent and registrar, replacing TSX Trust Company, effective September 1, 2026. Additionally, the company disclosed that US$240,000 in finder's fees were paid in connection with its acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program, which closed on April 13, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard